Equities

Fulgent Genetics Inc

Fulgent Genetics Inc

Actions
  • Price (EUR)20.40
  • Today's Change0.20 / 0.99%
  • Shares traded0.00
  • 1 Year change-21.84%
  • Beta--
Data delayed at least 15 minutes, as of Sep 19 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments424526450
Total Receivables, Net5775143
Total Inventory------
Prepaid expenses20225.96
Other current assets, total5.834.2812
Total current assets508628612
Property, plant & equipment, net969971
Goodwill, net2214351
Intangibles, net14315136
Long term investments424327485
Note receivable - long term------
Other long term assets433924
Total assets1,2351,3861,279
LIABILITIES
Accounts payable152320
Accrued expenses312518
Notes payable/short-term debt01521
Current portion long-term debt/capital leases1.736.580.33
Other current liabilities, total251846
Total current liabilities7388105
Total long term debt3.765.221.40
Total debt5.492723
Deferred income tax149.840.73
Minority interest(2.82)3.197.13
Other liabilities, total11135.41
Total liabilities99119120
SHAREHOLDERS EQUITY
Common stock0.000.000.00
Additional paid-in capital502487502
Retained earnings (accumulated deficit)633801658
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total1.21(21)(0.76)
Total equity1,1361,2671,159
Total liabilities & shareholders' equity1,2351,3861,279
Total common shares outstanding302930
Treasury shares - common primary issue2.761.810
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.